-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
22 Feb 2021Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)
19 Feb 2021Immunicum AB (publ) Announces Year-End Results 2020
18 Feb 2021
Latest Corporate presentation
Immunicum Company PresentationNews
-
Corporate Presentation – February 2021
22 Feb 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020 -
Transaction Webcast Details
18 Nov 2020 -
Allogeneic inflammatory dendritic cells, Mimicking anti-viral innate immunity against cancer
13 Oct 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
